Compare TG Therapeutics Inc (TGTX) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $25.99 (market cap $2.03B). The key difference: TG Therapeutics Inc is far larger — about 4× Direxion Daily 20 Year Treasury Bull 3X Shares's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 28 Days on average.
| TGTX | TMF | |
|---|---|---|
Market Cap | $8.16B | $2.03B |
Volume | 1,735,121 | 12,241,664 |
Sector | Health | Fixed Income |
52-Week High | $59.06 | $44.14 |
52-Week Low | $26.94 | $25.19 |
Typical Hold Time | 16 Days | 28 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
TMF (Direxion Daily 20+ Year Treasury Bull 3X ETF) trades at $25.99, up 3.01% with increased trading volume. Technical indicators show a bearish trend with moving averages signaling caution, while oscillators remain neutral. The ETF saw strong trading volume of 5.25 million shares, indicating heightened investor interest in long-term Treasury exposure.
As a leveraged Treasury ETF, TMF offers amplified exposure to long-term bond performance but carries significant volatility risks. Current market conditions suggest cautious positioning given bearish technical signals and interest rate sensitivity. The dividend payment scheduled for September 2026 provides modest income potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
